Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
GlobalData on MSN22h
EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myelomaCommittee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...
Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...
Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback